Queen’s University announced today that the NCIC Clinical Trials Group (NCIC CTG) has developed and will lead an international clinical trial of a new class of cancer drug aimed at curing non-small cell lung cancer (NSCLC) in patients who have had surgery and chemotherapy for disease confined to the lung. The academic-led trial will impact lung cancer patients following standard treatment.  Lung cancer is the second most common cancer in North America and is the leading cancer killer in both men and women.

NSCLC accounts for 80-85 per cent of all lung cancer cases.

The new drug, MEDI4736 (AstraZeneca), is one of a new class of pharmaceuticals that helps the body’s immune system recognize and attack cancer. Drugs in this class have already been approved for use in patients with malignant melanoma.

“This trial will test a new drug from an emerging class of agents that doesn’t directly kill cancer cells but instead improves our own immune system’s ability  to fight and kill the cancer cells,”  says trial leader Glen Goss, an oncologist and clinician investigator at The Ottawa Hospital. “This is a new way of fighting cancer and therefore we are moving these drugs into the earliest stage of lung cancer treatment to meet a major unmet need.”

The trial is being conducted internationally, with collaboration from the Intergroupe Francophone de Cancerologie Thoracique (France), the National Cancer Institute, Naples (Italy),   the Australasian Lung Cancer Trials Group &  National Health and Medical Research Council Clinical Trials Centre (Australia), the Spanish Lung Cancer Group, the Dutch Society for Pulmonology and Tuberculosis (NVALT), the Central and East European Oncology Group, the Korean Cancer Study Group and the National Cancer Centre Singapore.

“This is one of the most significant research funding announcements in the history of Queen’s,” says Principal Daniel Woolf. “It is very exciting, not only to know that this potentially life-saving research is happening right here in our midst, but also because it is allowing us to collaborate and build important relationships with researchers all over the world.”

“This trial is being completed internationally and includes academic physicians around the world,” says NCIC CTG director Janet Dancey. “This is the first trial in the world to test this new drug in the setting of early lung cancer treatment. We are always very grateful for ongoing support from the Canadian Cancer Society and Canadian Cancer Society Research Institute - without them, we would not be able to lead such critical cancer trials."

The trial will be open to 1,100 patients in Canada and around the world. Patients wishing to join the trial should speak to their oncologists about their treatment options. Approximately 25 institutions from across Canada will participate. Information about participation will also be available on clinicaltrials.gov and cancerview.ca

A Canadian leader in bullying prevention, Queen’s University researcher Wendy Craig was honoured Monday with the Social Sciences and Humanities Research Council of Canada’s Partnership Award. One of five SSHRC Impact Awards, the honour recognizes a SSHRC‑funded formal partnership for its outstanding achievement in advancing research.

Communications Officer Anne Craig sat down with Dr. Craig to talk about her work and what the award means to her.

Anne Craig: Why did you choose this field of research?

Wendy Craig: I fell into what I do by accident. During my PhD I was involved in a study with Debra Pepler where we were looking at aggressive children’s interactions on the playground. When we filmed them to find out what was happening on the playground, we saw that the playground was really aggressive. In that initial study, through naturalist observation, we found that children were bullying each other once every seven and a half minutes and they were aggressive towards each other once every two minutes. That study really defined and launched my career.  It ignited a strong interest in conducting applied research to understand how to support children and youth to develop optimally and have safe, healthy and respectful relationships. 

By working as a researcher and getting that research into the hands of practitioners and people who work with children, I can be more effective in having a larger impact on the health and well-being of Canadian children and youth.

AC: What is the current focus of your work?

WC: In addition to my work as a professor and researcher, I am the scientific co-director of PREVNet along with Dr. Pepler at York University.  PREVNet is comprised of more than 125 researchers across the country and 63 national organizations that work with children and youth. Its goal is to provide practitioners with the scientific information that they need to be more effective in their practice. We also want practitioners to identify the burning questions we should tackle as researchers. My work has become about knowledge mobilization and bridging the gap between science, practice and policy through the process of bringing researchers and organizations together to co-create research, resources and tools.

AC: Why is your work important?

WC: I believe that this work is important because it has to do with the health and well-being of children and youth. We recently finished a study for the Public Health Agency of Canada where we found that high-quality relationships with parents, peers, teachers, adults at school and the community positively impact physical and mental health outcomes, as well as academic and social ones. The concern Dr. Pepler and I had when we did that study was fewer children in Canada are reporting having high-quality relationships with parents, teachers, schools, and in the neighborhood. Bullying is a relationship problem and is related to long-term negative effects.  We have learned that children don’t grow out of bullying; it’s a problem that grows more significant as they get older. Part of what we do is look at how we minimize that long-term impact through prevention and intervention.

AC: What does the Partnership Award mean for you and your career?

WE: The award really recognizes the work of the network. This work could not be as effective without all members of the network contributing their unique skills, expertise, resources, dedication and time. Over time, through the generous funding of SSHRC through the National Centres of Excellence program, we have built a network that has a common vision, and is based on the foundation of trusting relationships. This award celebrates the incredible accomplishments that happen when outstanding organizations, researchers and students come together to co-create projects that are driven by science and meet the needs of our partners. Relationships matter to create an effective network that has conducted more than 200 projects in the last seven years. Creating PREVNet was a dream and we are excited we are now having an impact and making a difference in the lives of Canadian youth.

AC: What is your focus for the future?

WE: There is much work to do in Canada to improve children and youth development.  We rank 25 out of 28 on relationships. Given that healthy development depends on healthy relationships, we need to engage and support adults in all the places that children and youth live, learn, work and play.  We will work with our partners to continue to co-create research projects, and develop evidence-based education and training, assessment and evaluation tools, prevention and intervention strategies, and enhanced policy.  Through PREVNet we are leading the world in an unprecedented manner in creating a social-cultural change in reducing bullying through promoting relationships. 

Queen’s University has been awarded $1.4M in funding from the Canada Accelerator and Incubator Program (CAIP) to strengthen the innovation ecosystem in Eastern Ontario.  This award is part of a larger award that is also funding co-applicants Invest Ottawa and Wesley Clover International.  The Queen’s allocation will enable Innovation Park and PARTEQ Innovations to deliver a variety of virtual and physical incubation services and acceleration programs to high potential startups and emerging SMEs in Kingston and other areas of Eastern Ontario.

“We are delighted to be working with regional partners, Invest Ottawa and Wesley Clover, and local partner Launch Lab, to deliver an integrated Eastern Ontario Business Accelerator,” says Dr. Steven Liss, Vice-Principal (Research). “By combining and leveraging the strengths of the partners, this collaboration will expand programs and services available to high potential startups and SMEs in the region.”

The Honourable Royal Galipeau, MP for Ottawa-Orléans, announced the five year funding award in Ottawa on October 31.  Mr. Galipeau was joined by The Honourable Ed Holder, Minister of State (Science and Technology), National Research Council of Canada (NRC) Vice President, Bogdan Ciobanu, Invest Ottawa President and CEO, Bruce Lazenby, Wesley Clover Founder and Chairman, Sir Terrence Matthews, and, representing Queen’s University, PARTEQ Innovations Vice-President Finance & Administration, Paul Vickers.

 “The strength of the collaboration is in the diversity of partners and services and the broad coverage the partners are able to provide across Eastern Ontario”, says Janice Mady, Director of Industry Partnerships & Innovation Park. 

“We look forward to working closely with this unique group of collaborators to support the goal of strengthening the Eastern Ontario innovation ecosystem,” says PARTEQ President and CEO, Jim Banting.

CAIP will provide five years of funding to 15 outstanding accelerators and incubators in Canada that meet strict eligibility and selection criteria.  The contributions, which require 1:1 matching funds from eligible sources, support incremental activities that expand the overall service offerings to early-stage firms and entrepreneurs, and promote a higher output of SMEs that are investment-ready and able to develop into sustainable, high-growth businesses.

To read the official CAIP announcement, visit the website.

Queen’s University professor Jean Côté is joining an elite group of international researchers and members of the International Olympic Committee (IOC) this week to discuss training and development in youth sport.

The handpicked group of 16 researchers, along with members of the IOC, will evaluate the current science and practices related to developing young athletes. From that discussion, the group will draft recommendations and guidelines to ensure young athletes progress in a healthy manner.

Dr. Côté will present to the group his research on effective coaching.

“I will argue that we need to relax the structure of youth sports in general – youth organized sport is over-coached and over-structured.  The achievement of long-term participation, elite performance, and personal development through sport are objectives that are compatible and do not require specialized programs and complex structures” he says.

One of the biggest challenges at the conference, Dr. Côté anticipates, will be reaching a consensus decision with such a wide range of expertise in the same room. The participants are presenting on a variety of topics including athlete development frameworks, talent identification, scheduling and overload, injury prevention and eating disorders. By April 2015, the group must have a consensus paper on youth athlete development ready for publication in the IOC-supported injury prevention and health protection edition of the British Journal of Sports Medicine.

“There are going to be a lot of conflicting ideas presented at the conference, but we have to focus on our goal of youth development and work past that,” says Dr. Côté. “It’s exciting to be associated with this level of research and it also shows the IOC cares about the development of youth. We are looking at the whole child and that is a very healthy approach.”

The conference takes place from Nov. 5-7 at the IOC headquarters in Lausanne, Switzerland.